Suppr超能文献

通过结构延伸增强碳酸酐酶 IX 活性位点内的尾部疏水相互作用:新型 N-取代色酮-SLC-0111 杂化物作为碳酸酐酶抑制剂和抗肿瘤剂的设计与合成。

Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: Design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents.

机构信息

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.

出版信息

Eur J Med Chem. 2019 Jan 15;162:147-160. doi: 10.1016/j.ejmech.2018.10.068. Epub 2018 Nov 2.

Abstract

Herein we report the design and synthesis of novel N-substituted isatins-SLC-0111 hybrids (6a-f and 9a-l). A structural extension approach was adopted via N-alkylation and N-benzylation of isatin moiety to enhance the tail hydrophobic interactions within the carbonic anhydrase (CA) IX active site. Thereafter, a hybrid pharmacophore approach was utilized via merging the pharmacophoric elements of isatin and SLC-0111 in a single chemical framework. As planned, a substantial improvement of inhibitory profile of the target hybrids (Ks: 4.7-86.1 nM) towards hCA IX in comparison to N-unsubstituted leads IVa-c (Ks: 192-239 nM), was achieved. Molecular docking of the designed hybrids in CA IX active site unveiled, as planned, the ability of N-alkylated and N-benzylated isatin moieties to accommodate in a wide hydrophobic pocket formed by T73, P75, P76, L91, L123 and A128, establishing strong van der Waals interactions. Hybrid 6c displayed good anti-proliferative activity under hypoxic conditions towards breast cancer MDA-MB-231 and MCF-7 cell lines (IC = 7.43 ± 0.28 and 12.90 ± 0.34 μM, respectively). Also, 6c disrupted the MDA-MB-231 cell cycle via alteration of the Sub-G phase and arrest of G-M stage. Additionally, 6c displayed significant increase in the percent of annexinV-FITC positive apoptotic cells from 1.03 to 18.54%. Furthermore, 6c displayed potent VEGFR-2 inhibitory activity (IC = 260.64 nM). Collectively, these data suggest 6c as a promising lead molecule for the development of effective anticancer agents.

摘要

在此,我们报告了新型 N-取代色酮-SLC-0111 杂化物(6a-f 和 9a-l)的设计和合成。通过色酮部分的 N-烷基化和 N-苄基化采用了结构扩展方法,以增强碳酸酐酶(CA)IX 活性部位内的尾部疏水相互作用。此后,通过将色酮和 SLC-0111 的药效团元素合并到单个化学结构中,采用了杂合药效团方法。按计划,与 N-未取代的先导物 IVa-c(Ks:192-239 nM)相比,目标杂化物对 hCA IX 的抑制谱有了实质性改善(Ks:4.7-86.1 nM)。设计的杂化物在 CA IX 活性部位的分子对接揭示了,如计划的那样,N-烷基化和 N-苄基化色酮部分能够容纳由 T73、P75、P76、L91、L123 和 A128 形成的宽疏水口袋,建立强范德华相互作用。杂化物 6c 在缺氧条件下对乳腺癌 MDA-MB-231 和 MCF-7 细胞系表现出良好的抗增殖活性(IC = 7.43 ± 0.28 和 12.90 ± 0.34 μM)。此外,6c 通过改变 Sub-G 期和 G-M 期阻滞破坏 MDA-MB-231 细胞周期。此外,6c 使 AnnexinV-FITC 阳性凋亡细胞的百分比从 1.03%显著增加到 18.54%。此外,6c 对 VEGFR-2 表现出很强的抑制活性(IC = 260.64 nM)。总的来说,这些数据表明 6c 是开发有效抗癌药物的有前途的先导分子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验